(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Summit Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast SMMT's revenue for 2026 to be $22,532,484,134, with the lowest SMMT revenue forecast at $1,886,371,447, and the highest SMMT revenue forecast at $43,178,596,821. On average, 3 Wall Street analysts forecast SMMT's revenue for 2027 to be $63,071,646,262, with the lowest SMMT revenue forecast at $4,753,061,914, and the highest SMMT revenue forecast at $164,337,115,663.
In 2028, SMMT is forecast to generate $884,797,328,535 in revenue, with the lowest revenue forecast at $58,819,141,181 and the highest revenue forecast at $1,843,475,063,190.